Iovance Biotherapeutics, Inc. (IOVA)

Last Price:  

Company Description

Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-259.58M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 5.45
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -41.12%
Return on Assets (Trailing 12 Months) -35.99%
Current Ratio (Most Recent Fiscal Quarter) 11.01
Quick Ratio (Most Recent Fiscal Quarter) 11.01
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $4.48
Earnings per Share (Most Recent Fiscal Quarter) $-0.53
Earnings per Share (Most Recent Fiscal Year) $-1.88
Diluted Earnings per Share (Trailing 12 Months) $-1.91
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 155.03M
Free Float 141.54M
Market Capitalization $4.06B
Average Volume (Last 20 Days) 1.08M
Beta (Past 60 Months) 0.84
Percentage Held By Insiders (Latest Annual Proxy Report) 8.70%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%